Highlights of This Issue 5839

SPECIAL FEATURES

CCR Translations

5841 Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma
Michael R. Harrison and Daniel J. George
See article p. 6021

Molecular Pathways

5844 Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone
James L. Mohler, Mark A. Titus, and Elizabeth M. Wilson

5850 ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease
Maria Soledad Sosa, Alvaro Avivar-Valderas, Paloma Bragado, Huei-Chi Wen, and Julio A. Aguirre-Ghiso

Review

5858 Thrombotic Microangiopathy with Targeted Cancer Agents
John A. Blake-Haskins, Robert J. Lechleider, and Robert J. Kreitman

HUMAN CANCER BIOLOGY

5867 Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System
Andrew V. Kossenkov, Anil Vachani, Celia Chang, Calen Nichols, Shere Bilouin, Wenhwai Horng, William N. Rom, Steven M. Albeda, Michael K. Showe, and Louise C. Showe

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy
Sarah Minner, Malaika Enodien, Hüseyin Sirma, Andreas M. Luebke, Antje Krohn, Pascale S. Mayer, Ronald Simon, Pierre Tennstedt, Julia Müller, Laura Scholz, Jan C. Brase, Alvin Y. Liu, Hartmut Schlüter, Klaus Pantel, Udo Schumacher, Carsten Bokemeyer, Thomas Steuber, Markus Graefen, Guido Sauter, and Thorsten Schlimm

Characterization of a Cleavage Stimulation Factor, 3' pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer
Masato Aragaki, Koji Takahashi, Hirohiko Akiyama, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, and Yataro Daigo

CANCER THERAPY: PRECLINICAL

5901 Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma
Xianbiao Xie, Markus P.H. Ghadimi, Eric D. Young, Roman Belousov, Quan-sheng Zhu, Juehui Liu, Gonzalez Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso, Jason L. Hornick, Alexander J. Lazar, and Dina Lev

5913 Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

5926 Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody
Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan

5935 Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Kelly M. Quesnelle and Jennifer R. Grandis
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5945</td>
<td>Targeting Human B-cell Malignancies through Ig Light Chain–Specific</td>
<td>Jinsheng Weng, Soung-Chul Cha, Satoko Matsueda, Gheath Alatrash, Michael S. Popescu, Qing Yi, Jeffrey J. Mouldrem, Michael Wang, Sattva S. Neelapu, and Larry W. Kwak</td>
</tr>
<tr>
<td>5953</td>
<td>Curcumin Treatment Suppresses IKKβ Kinase Activity of Salivary Cells</td>
<td>Suejung G. Kim, Mysore S. Veena, Saroj K. Basak, Eugene Han, Tracey Tajima, David W. Gjertson, Joshua Starr, Ofer Eidelman, Harvey R. Pollard, Meera Srivastava, Eri S. Srivatsan, and Marilene B. Wang</td>
</tr>
<tr>
<td>5962</td>
<td>Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic</td>
<td>Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen, Pernille Foged Jensen, Jette Wagtberg Sen, Thomas Kjaersgaard Jørgensen, Adam Hey, and Michael Krugh</td>
</tr>
<tr>
<td>5973</td>
<td>ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2 × 100% / Mcl-1 low Profile and Synergizes with Other Antineoplastic Agents</td>
<td>Cyrille Touzeau, Christelle Dousset, Linda Bodet, Patricia Gomez-Bougie, Stéphanie Bonnau, Anne Moreau, Philippe Moreau, Catherine Pellat-Decencyn, Martine Amiot, and Steven Le Gouill</td>
</tr>
<tr>
<td>6021</td>
<td>Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in</td>
<td>Irfan Kayani, Norbert Avril, Jamshed Bomanji, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamash, Kevin Sharpe, Louise Lim, John Dickson, Peter Ell, Andrew Reynolds, and Thomas Powles</td>
</tr>
<tr>
<td>6029</td>
<td>Prognostic Impact of ΔTAp73 Isoform Levels and Their Target Genes in Colon Cancer Patients</td>
<td>Beatriz Soldevilla, Raquel Diaz, Javier Silva, Yolanda Campos-Martín, Concepción Muñoz, Vanessa García, José M García, Cristina Peña, Mercedes Herrera, Marta Rodriguez, Irene Gómez, Nagat Mohamed, Margarita M. Marques, Félix Bonilla, and Gemma Domínguez</td>
</tr>
<tr>
<td>6040</td>
<td>Upregulation of Rac GTPase-Activating Protein 1 Is Significantly</td>
<td>Suk Mei Wang, London Lucien P.J. Ooi, and Kam M. Hui</td>
</tr>
<tr>
<td>6052</td>
<td>Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer</td>
<td>Aung Naing, Razelle Kurzrock, Angelika Burger, Sachin Gupta, Xiudong Lei, Naifa Buisaidy, David Hong, Helen X. Chen, Lawrence A. Doyle, Lance K. Heilbrun, Eric Rohren, Chaan Ng, Chandnap Chandhasin, and Patricia LoRusso</td>
</tr>
</tbody>
</table>
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response

ABOUT THE COVER
Interleukin-6 (IL-6) has tumor-promoting actions on both malignant and stromal cells in a range of experimental cancer models. In addition, high plasma IL-6 levels are associated with poor prognosis in ovarian cancer, but there is little information as to the source of this IL-6. Ovarian cancer biopsies were stained for IL-6 (left) and automated algorithms used to assess both malignant (right) and stromal (middle) compartments. Expression levels were quantified using an autoscore that combined both the intensity and density of positive pixels. IL-6 staining was seen in both the malignant and nonmalignant cells, but was significantly higher in the malignant cell areas. For further details, see Coward and colleagues on page 6083 of this issue.
Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/17/18

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.